Peer-reviewed veterinary case report
Outpatient ketamine-lidocaine infusions for cancer pain in dogs
By Iocolano, Kari E et al.·Published in Journal of the American Veterinary Medical Association·2025·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of outpatient intravenous ketamine-lidocaine infusions for the palliation of cancer pain in dogs and cats.
- Species:
- dog
Plain-English summary
A group of 105 dogs and 9 cats with cancer pain received outpatient intravenous infusions of a combination of ketamine and lidocaine to help manage their discomfort. Most of the pets had tumors like osteosarcoma or oral squamous cell carcinoma and were also given other pain medications. After the first infusion, about 76% of the animals showed improvement in their symptoms. The treatment was well-tolerated, and it appears to be a helpful option for pets suffering from severe cancer pain when used alongside other therapies.
People also search for: dog cancer pain relief · cat cancer treatment options · ketamine lidocaine infusion for pets · managing pain in dogs with cancer
Abstract
OBJECTIVE: To evaluate the clinical benefit and adverse events following outpatient intravenous (IV) ketamine-lidocaine (KL) infusions for palliation of cancer pain in dogs and cats. METHODS: Medical records from 15 years (2008 to 2023) were searched and data reviewed retrospectively. Animals were prescribed ketamine (0.15 mg/kg/h) and lidocaine (3 mg/kg/h in dogs and 1.5 mg/kg/h in cats) diluted in 250 mL (cats or dogs < 15 kg) or 500 mL (dogs ≥ 15 kg) of 0.9% saline administered IV at 2.5 mL/kg/h for 4 to 6 hours. RESULTS: A total of 105 dogs and 9 cats (114 animals) were included. The most common tumor types treated were appendicular osteosarcoma in dogs (n = 45 [43%]) and oral squamous cell carcinoma in cats (4 [44%]). All animals received concomitant oral analgesic medications. Animals received a median of 2 KL infusions (range, 2 to 49 KL infusions). The overall clinical benefit rate was 76% following the first KL infusion, as defined by an improvement in at least 1 evaluated clinical sign. The likelihood of clinical response was improved with a ketamine infusion rate ≥ 2 µg/kg/min, total ketamine dose of ≥ 0.5 mg/kg, and lidocaine infusion rate ≥ 25 µg/kg/min. CONCLUSIONS: Outpatient IV KL infusions were well-tolerated in dogs and cats with cancer and provided a high rate of clinical benefit when combined with standard anti-cancer and analgesic therapies. CLINICAL RELEVANCE: Management of cancer pain often requires multimodal analgesia. Given the clinical benefit and minimal toxicity observed with outpatient KL infusions, KL infusions should be considered as an adjunctive treatment to use in combination with anticancer therapy, oral and topical analgesics, and interventional therapies in dogs and cats for palliation of refractory cancer pain from advanced disease.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39724771/